Physician profile
Rahat Hussain
NPI 1669620761
$10,904.94
in general payments reported to CMS, 2019-2025
21 companies · $8,781 in 2025
The $8,781 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $22.76 · 2021: $283 · 2022: $390 · 2023: $501 · 2024: $655 · 2025: $8,781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,586 · Food and Beverage: $1,916 · Travel and Lodging: $1,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,586.17 |
| Food and Beverage | $1,915.71 |
| Travel and Lodging | $1,434.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $8,411.16 | 2021-2025 | Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $974.18 | 2019-2025 | Ofev, Jascayd |
| Abbott Laboratories | $464.16 | 2022-2023 | Aveir, Mitraclip |
| Merit Medical Systems INC | $186.64 | 2024 | Aero Stent and Delivery System |
| Astellas Pharma US INC | $136.65 | 2020-2025 | Cresemba |
| Boston Scientific Corporation | $130.15 | 2019-2023 | |
| Glaxosmithkline, LLC. | $92.26 | 2024-2025 | Nucala |
| Paratek Pharmaceuticals, INC. | $82.45 | 2023-2025 | Nuzyra |
| Pulmonx Corporation | $62.73 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Integra Lifesciences Corporation | $50.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.89 | 2019-2023 | |
| Grifols USA, LLC | $39.41 | 2025 | Prolastin-C Liquid |
| Adma Biomanufacturing LLC | $36.17 | 2023-2024 | |
| Genentech USA, INC. | $35.61 | 2019 | |
| Philips North America LLC | $32.97 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $30.11 | 2024 | Opsumit, Uptravi |
| Shionogi INC | $28.04 | 2025 | Fetroja |
| Abbvie INC. | $24.00 | 2024 | |
| Sandoz INC. | $17.12 | 2023 | Treprostinil |
| Astrazeneca Pharmaceuticals Lp | $15.61 | 2019 | |
| Pfizer INC. | $14.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahat Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.